155 related articles for article (PubMed ID: 3068036)
1. Octreotide: a synthetic analog of somatostatin.
Rosenberg JM
Drug Intell Clin Pharm; 1988 Oct; 22(10):748-54. PubMed ID: 3068036
[TBL] [Abstract][Full Text] [Related]
2. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.
Battershill PE; Clissold SP
Drugs; 1989 Nov; 38(5):658-702. PubMed ID: 2689136
[TBL] [Abstract][Full Text] [Related]
3. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
McKeage K; Cheer S; Wagstaff AJ
Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
Öberg K; Lamberts SW
Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
[TBL] [Abstract][Full Text] [Related]
5. Debut of a somatostatin analog: octreotide in review.
Zindel LR
Conn Med; 1989 Dec; 53(12):741-4. PubMed ID: 2558839
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects.
Harris AG
Gut; 1994; 35(3 Suppl):S1-4. PubMed ID: 7911441
[TBL] [Abstract][Full Text] [Related]
7. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
8. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.
Ludlam WH; Anthony L
Adv Ther; 2011 Oct; 28(10):825-41. PubMed ID: 21964965
[TBL] [Abstract][Full Text] [Related]
9. Octreotide, a new somatostatin analogue.
Katz MD; Erstad BL
Clin Pharm; 1989 Apr; 8(4):255-73. PubMed ID: 2653711
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW
Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295
[TBL] [Abstract][Full Text] [Related]
11. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.
Gillis JC; Noble S; Goa KL
Drugs; 1997 Apr; 53(4):681-99. PubMed ID: 9098666
[TBL] [Abstract][Full Text] [Related]
12. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of acromegaly with octreotide, a synthetic analog of somatostatin with extended action].
Arosio M; Bazzoni N; Faglia G
Minerva Endocrinol; 1990; 15(1):29-36. PubMed ID: 2274011
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin analogs and prednisone in advanced refractory thymic tumors.
Palmieri G; Montella L; Martignetti A; Muto P; Di Vizio D; De Chiara A; Lastoria S
Cancer; 2002 Mar; 94(5):1414-20. PubMed ID: 11920496
[TBL] [Abstract][Full Text] [Related]
16. [Somatostatin analog (octreotide) in clinical use: current and potential indications].
Meier R; Dierdorf R; Gyr K
Schweiz Med Wochenschr; 1992 Jun; 122(25):957-68. PubMed ID: 1621078
[TBL] [Abstract][Full Text] [Related]
17. [Octreotide, analog of somatostatin. Pharmacological properties and therapeutic applications in pituitary endocrine tumors].
Chanson P; Timsit J; Harris AG
Presse Med; 1993 Dec; 22(40):2009-16. PubMed ID: 7907419
[TBL] [Abstract][Full Text] [Related]
18. Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly.
Biermasz NR; Pereira AM; Frölich M; Romijn JA; Veldhuis JD; Roelfsema F
Am J Physiol Endocrinol Metab; 2004 Jan; 286(1):E25-30. PubMed ID: 14506078
[TBL] [Abstract][Full Text] [Related]
19. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.
Freda PU; Katznelson L; van der Lely AJ; Reyes CM; Zhao S; Rabinowitz D
J Clin Endocrinol Metab; 2005 Aug; 90(8):4465-73. PubMed ID: 15886238
[TBL] [Abstract][Full Text] [Related]
20. Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice.
Maggio ET; Grasso P
Regul Pept; 2011 Apr; 167(2-3):233-8. PubMed ID: 21329733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
